Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Wednesday 09 July, 2008

Summit Corporation PLC

AGM Statement





Summit Corporation plc
("Summit plc" or "the Company")

RESULTS OF ANNUAL GENERAL
MEETING

Oxford, UK, 9 July 2008 - Summit Corporation plc (AIM: SUMM), a UK
biotechnology company, announces that all the resolutions that were
proposed to shareholders were passed at its Annual General Meeting
held today.  In particular, the following resolutions were approved
by shareholders:

*          To increase the authorised share capital of the Company to
  £7,500,000
*          The Board has been granted authority to issue new shares
  up to a nominal value of £1,000,000
*          To adopt New Articles of Association to reflect changes to
  English company law
*          The re-election of the following Directors to the Board of
  Directors: Steven Lee and Richard Storer
*          To approve the Reports of the Directors and Auditors and
  the Accounts for the year ended 31 January 2008.  BDO Stoy Hayward
  LLP was also reappointed as the Auditors of the Company.

                              - ENDS -
For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Sylvie Berrebi / Emma Palmer
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a leading UK biotechnology company with a broad
preclinical and clinical pipeline, two world-leading technology
platforms and an innovative business model that is expected to
generate sustainable value for investors.
Summit is developing multiple drug programmes that target unmet
medical needs from which it intends to generate value by
out-licensing attractive late preclinical or early clinical stage
programmes in return for upfront, milestone and royalty payments.
Summit uses its scientific expertise to target orphan diseases,
neuro-disorders and infectious diseases.
Underpinning Summit's drug pipeline are two innovative technology
platforms: carbohydrate chemistry and zebrafish biology. These
platforms support existing programmes and also will be the source of
future programmes to replenish Summit's drug pipeline.  These
platform technologies also form the basis of the Company's profitable
service business.
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at www.summitplc.com.

---END OF MESSAGE---